查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1247465

2023-2030 年全球血液肿瘤检测市场

Global Hemato Oncology Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球血液肿瘤检测市场预计将实现利润丰厚的增长，到 2022 年将达到 2.8 亿美元，到 2030 年将达到 6.2 亿美元。 在预测期内（2023 年至 2030 年），该市场的复合年增长率为 4.8%。

血液肿瘤学结合了两个医学领域：研究血液的血液学和研究癌症的肿瘤学。 血液肿瘤学家接受过血癌和血液相关疾病的诊断、治疗和预防方面的培训。 血液肿瘤学领域涉及血液和相关癌症的治疗。

市场动态

药物诊断和服务的技术进步

市场的不断进步和技术先进的新产品的推出正在推动全球血液肿瘤检测市场的增长。 例如，2022 年 8 月，Thermo Fisher Scientific 宣布推出 CE-IVD (IVDD) 下一代测序和分析软件，以扩大精准肿瘤生物标誌物检测的范围。 同样，2022 年 6 月，Burning Rock Biotech Limited 获得了 OverC 多癌评估血液测试的 CE 标誌。 OverC 多癌推定血液检测是一种基于下一代测序仪 (NGS) 的定性体外诊断设备。 同样，2021 年 11 月，圣地亚哥和遗传联盟启动了 iHope Genetic Health 计划，旨在为全球数万名患有遗传病的人提供全基因组测序访问（WGS）。

个性化医疗意识的增强正在为市场创造有利可图的增长机会。

个性化医疗是一种快速发展的医疗实践，它使用个人的基因概况来做出预防、诊断和治疗疾病的决策。 了解患者的遗传概况后，医生可以选择最准确的药物和治疗方法，并使用适当的剂量和方案进行管理。 例如，2021 年 1 月，随着个性化医疗的作用不断扩大，FDA 承诺向医生提供有关设计新疗法的知识。 此外，欧洲癌症患者联盟 (ECPC) 将在 11 月领导第一个个性化医疗宣传月，ECPC 在为期一个月的名为“个性化医疗宣传月”的宣传活动中倡导癌症分子检测。宣传获得癌症的重要性：破译癌症密码”。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按产品/服务类型分类的摘要
  • 按技术分类的片段
  • 按癌症类型分类的摘要
  • 最终用户的片段
  • 区域摘要

第 4 章动力学

  • 影响因子
    • 司机
      • 药物诊断和服务方面的技术进步
      • 全球范围内血癌的患病率正在上升
    • 约束因素
      • 不利和不确定的赎回情景
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章按产品/服务类型

  • 仪器
  • 试剂和耗材
  • 服务内容

第八章技术

  • PCR（聚合□炼式反应）
  • IHC（免疫组织化学）
  • NGS（下一代测序）
  • 细胞遗传学
  • 其他

第 9 章按癌症类型分类

  • 白血病
    • 急性髓性白血病
    • 急性淋巴细胞白血病
    • 其他
  • 淋巴瘤
  • 多发性骨髓瘤
  • 其他

第 10 章最终用户

  • 临床实验室
  • 医院
  • 学术和研究机构等
  • 其他

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 俄罗斯
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第13章公司简介

  • F. Hoffman-La Roche Ltd.
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • Abbott Laboratories
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • ICON PLC
  • Archerdx, Inc.
  • Invivoscribe, Inc.
  • Adaptive Biotechnologies

第14章 附录

简介目录
Product Code: CD1347

Market Overview

The global hemato oncology Testing market reached US$ 280 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).

Hematologic oncology integrates two fields of medicine: hematology, the study of the blood, and oncology, the study of cancer. Hematologic oncologists are trained in diagnosing, treating, and preventing blood cancers and blood-related disorders. The field of haemato-oncology deals with the treatment of blood and related cancers.

Market Dynamics

Technological advancements in drug diagnosis and services

The growing advancements and new technologically advanced product introductions into the market are boosting the global hemato oncology testing market growth. For instance, in August 2022, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analysis software to extend access to precision oncology biomarker testing. Likewise, in June 2022, Burning Rock Biotech Limited was granted a CE marking for its OverC multi-cancer estimation blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. Similarly, in November 2021, SAN DIEGO and Genetic Alliance created the iHope Genetic Health program targeted at delivering whole-genome sequencing access (WGS) to tens of thousands of individuals all over the globe affected by genetic disease.

Growing awareness regarding personalized medicines is presenting the market with lucrative growth opportunities.

Personalized medicine is a blossoming practice of medicine that employs an individual's genetic profile to direct decisions formed for the prevention, diagnosis, and treatment of the disorder. Knowledge of a patient's genetic profile can aid physicians to choose the most accurate medication or therapy and administer it utilizing the appropriate dose or regimen. The growing awareness and efforts to implement personalized medicine are providing the market with very lucrative growth opportunities For instance, in January 2021, the FDA declared its involvement in providing physicians with knowledge on the designing of novel therapies as the role of personalized medicine keeps on expanding. Furthermore, the European Cancer Patient Coalition (ECPC) lead the first Personalized Medicine Awareness Month throughout November, the ECPC promoted the significance of access to cancer molecular testing during a month-long advocacy campaign called, Personalized Medicine Awareness Month: Cracking the Cancer Code.

Segment Analysis

The global hemato oncology testing market is segmented based on Product & Services, Cancer Type, Technology, and region.

Owing to growing new technological advancements, product launches, and recent development

The increasing market developments such as collaborations, and product launches among others are boosting the services segment growth during the forecast period. For instance, in August 2020 Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System. Also, in May 2022, the Qatar Foundation (QF) division of the Qatar Genome Program (QGP), and Thermo Fisher Scientific partnered for the advancement of genomic research and clinical applications of predictive genomics in Qatar as a step in the direction of expanding the benefits of precision medicine all over the Arab populations worldwide. Similarly, in August 2022, Mount Sinai Health System and the Icahn School of Medicine introduced a new human genome sequencing research project known as the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). Thus, the mentioned data indicates that the services segment will dominate the global hemato-oncology testing market throughout the forecast period.

Geographical Penetration

The strong presence of major players and increased awareness about the use of eco-friendly products

North America dominates the global hemato oncology testing market during the forecast period, owing to the growing cases of leukemia, better reimbursement policies, and the presence of key market players holding the majority of the market in this region. For instance, according to the Canada Cancer Society report that there were over 6,700 Canadians diagnosed with leukemia, of which around 4,000 were men and about 2,700 were women in 2021. Also, the American Cancer Society documented that approximately 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were diagnosed in the United States in 2022. Also, acute myeloid leukemia (AML) made up only about 1% of all cancers. Furthermore, Abbott Laboratories, Thermofisher Scientific, and Illumina are among the key market players holding the majority of market share based in the North American region ensuring the dominance of the region over the global market.

Competitive Landscape

The major global players include F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.

COVID-19 Impact Analysis

By Type of Product & Service

  • Instruments
  • Reagents & Consumables
  • Services

By Technology

  • PCR (Polymerase Chain Reaction)
  • IHC (immunohistochemical)
  • NGS (Next-Generation Sequencing)
  • Cytogenetics
  • Others

By Cancer Type

  • Leukemia
    • Acute Myeloid Leukemia
    • Acute Lymphocytic Leukemia
    • Others
  • Lymphoma
  • Multiple myelomas
  • Others

By End-user

  • Clinical Laboratories
  • Hospitals
  • Academic & Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In 2022, the US FDA granted approval to F. Hoffmann-La Roche Ltd. (Switzerland) for its cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma.
  • In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) formed a 15-year non-exclusive collaboration with Illumina to extend the adoption of NGS-based testing in oncology.
  • In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) formed a partnership to design a blood-based companion diagnostic (CDx) test for the treatment of diffuse large B-cell lymphoma (DLBCL), one of the most typical lymphoid cancers.

Why Purchase the Report?

  • To visualize the global Hemato Oncology Testing- market segmentation based on product, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Hemato Oncology Testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Hemato Oncology Testing market report would provide approximately 69 tables, 71 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type of Products & Services
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Type of cancer
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements In Drug Diagnosis And Services
      • 4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of Product & Service

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 7.1.2. Market Attractiveness Index, By Type of Product & Service
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Reagents & Consumables
  • 7.4. Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR (Polymerase Chain Reaction) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. IHC (immunohistochemical)
  • 8.4. NGS (Next-Generation Sequencing)
  • 8.5. Cytogenetics
  • 8.6. Others

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type
  • 9.2. Leukemia*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Acute Myeloid Leukemia
    • 9.2.4. Acute Lymphocytic Leukemia
    • 9.2.5. Others
  • 9.3. Lymphoma
  • 9.4. Multiple myelomas
  • 9.5. Others

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.1.2. Market Attractiveness Index, By End-user
  • 10.2. Clinical Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospitals
  • 10.4. Academic & Research Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. UK
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Russia
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. F. Hoffman-La Roche Ltd.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Abbott Laboratories
  • 13.3. Qiagen N.V.
  • 13.4. Thermo Fisher Scientific, Inc.
  • 13.5. Illumina, Inc.
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. ICON PLC
  • 13.8. Archerdx, Inc.
  • 13.9. Invivoscribe, Inc.
  • 13.10. Adaptive Biotechnologies

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us